Crossmark

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

Published Online: 2016-06-23

Published Print: 2016-12

Authors

Ivanoiu, Adrian

Pariente, Jérémie

Booth, Kevin

Lobello, Kasia

Luscan, Gerald

Hua, Lisa

Lucas, Prisca

Styren, Scot

Yang, Lingfeng

Li, David

Black, Ronald S.

Brashear, H. Robert

McRae, Thomas
Funding

Funding for this research was provided by:

Pfizer Foundation

Janssen Research and Development
License Information

Text and Data Mining valid from 2016-06-23

Version of Record valid from 2016-06-23
More Information

Article History

Received: 9 March 2016

Accepted: 18 May 2016

First Online: 23 June 2016

Document is current